Scholar Rock wins FDA approval for SMA muscle-loss drug — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Scholar Rock received FDA approval on Friday for Isembyld, the first-ever therapy to target loss of muscle in spinal muscular atrophy (SMA)
- Isembyld is approved for adults and children 2 years and older who are currently receiving SMA therapies that target the SMN2 gene, a key gene for neurons controlling movement
- A late-stage clinical trial found that when combined with an SMN2-targeting drug, young patients' motor skills improved after a year while placebo patients declined — a statistically significant difference
- David Hallal, Scholar Rock's CEO, called the approval "a defining moment for the SMA community" and said the company overcame "decades of failed industry-wide efforts to unlock the potential of myostatin inhibition"
Why it matters: This is the first drug approved specifically to preserve or rebuild muscle in SMA patients, addressing a gap left by existing SMN2-targeting therapies that protect motor neurons but don't directly combat muscle wasting. For the rare-disease SMA community — where patients risk progressive loss of movement despite current treatments — the approval gives clinicians a second mechanism to combine against the disorder.
Ask SkimNews
